Back to search
An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE).
Data up to Jan 2025
Published2010
Citations14
References0
Total Citations Per Year
Abstract
References (0)
No references found
Cited By (0)
No citing papers found in database